Caribou Biosciences halts CAR-T programs and seeks strategic alternatives after failing to secure funding

Caribou Biosciences is halting clinical development of its only remaining therapeutic candidates, vispa-cel and CB-011, and exploring strategic alternatives such as a merger or asset sale. Despite securing FDA alignment for a Phase 3 trial of vispa-cel, the Berkeley-based biotech failed to raise the necessary capital due to a freezing financing environment for allogeneic CAR-T therapies. Consequently, Caribou is implementing a substantial workforce reduction expected to cost $15 million to $19 million, leaving a skeleton crew to wind down the business.

Discontinuation of clinical-stage programs

• ▪The discontinuation of vispa-cel and CB-011 represents the end of Caribou Biosciences' active therapeutic pipeline and clinical-stage research and development activities.
• ▪Caribou Biosciences announced on October 6, 2026, that it is discontinuing its two remaining clinical-stage allogeneic CAR-T cell therapy programs, vispa-cel and CB-011.

Evaluation of strategic alternatives

• ▪Caribou Biosciences' Board of Directors approved initiating a process to evaluate strategic alternatives, which may include a merger, acquisition, sale of assets, or business combination.
• ▪Caribou Biosciences engaged Wedbush Securities Inc. as its exclusive financial advisor to assist in the strategic evaluation process.

Workforce reduction and restructuring

• ▪Caribou Biosciences will implement a substantial reduction in workforce that is expected to be mostly completed in the fourth quarter of 2026.
• ▪Caribou Biosciences expects to incur restructuring costs of approximately $15 million to $19 million in connection with the workforce reduction.
• ▪The workforce reduction will leave a limited number of employees to complete the strategic alternatives process and wind down Caribou Biosciences.

Development and trial data of vispa-cel

• ▪Caribou Biosciences' vispa-cel, a Phase 3-ready allogeneic CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, has a Food and Drug Administration-agreed pivotal Phase 3 trial design.
• ▪In the Phase 1 ANTLER trial, vispa-cel demonstrated an 82% overall response rate and a 67% complete response rate in patients with second-line large B cell lymphoma.

Development and trial data of CB-011

• ▪Phase 1 data from the CaMMouflage study of CB-011 showed a 92% overall response rate in patients treated with the therapy.
• ▪Caribou Biosciences' CB-011 is an allogeneic CAR-T cell therapy designed to target the BCMA protein to treat relapsed or refractory multiple myeloma.

Funding challenges for allogeneic therapies

• ▪Caribou Biosciences cited a challenging financing environment for allogeneic CAR-T cell therapies as the reason it could not secure the capital necessary to advance its programs.
• ▪Biopharma companies and investors are increasingly shifting focus and funding away from allogeneic therapies toward in vivo and autologous CAR-T cell therapies.

Caribou stock performance

• ▪Caribou Biosciences went public in July 2021, and its shares briefly topped $30 apiece in September 2021.
• ▪Following the announcement of the program halts and strategic review, Caribou Biosciences' stock fell approximately 40% to 43% in trading on October 6 and October 7, 2026.

Debatable claims

• ▪The biopharma industry's shift away from allogeneic CAR-T funding is premature
• ▪Allogeneic CAR-T therapies can match the durability of autologous treatments